Unlike anti-PD-1 treatment, TRIMELVax induced potent tumor infiltration of CD8+ T cells, being CD8+/CD4+ T-cell ratio significantly enhanced by TRIMELVax (figure 6B). Here, CD4 is linked to neoplasm.